Please assess the completion status of the following clinical trial:

Trial Title: Mechanical Bowel Preparation and Oral Antibiotics Before Colon Cancer Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 or more~* Scheduled to undergo elective restorative laparoscopic segmental colectomy for colon cancer~* With Signed consent~* And affiliated to the French social security system~Exclusion Criteria:~* Emergent surgery~* Scheduled total or subtotal colectomy (defined as a colectomy extended from the right colon to a least the left colonic angle)~* Scheduled transverse colectomy~* Scheduled associated proctectomy~* Scheduled associated concomitant resection of another organ (liver, etc.), except the abdominal wall~* Previous segmental colectomy~* Associated inflammatory bowel disease~* Active bacterial infection at the time of surgery or recent antimicrobial therapy (up to 2 weeks before surgery)~* Patients with known colonization with multidrug-resistant enterobacteriacea~* History of allergy or contraindication to the Ornidazole, Gentamycin, X-PREP or to any of the excipients of the drugs used.~* Cirrhosis of grade B and C (Child-Pugh classification)~* Myasthenia~* Allergy to one of the other treatments administered for the purpose of the trial (including betadine)~* Patient suffering from severe central neurologic diseases, fixed or progressive.~* Pregnant patients~* Refusal to participate or inability to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1)  MBP and oral antibiotics  group (Type: EXPERIMENTAL): Sennosides colonic preparation Oral Gentamycin Oral Ornidazole~* Sennosides colonic preparation (X-PREP) :~  1 per day, on day -2 and day -1.~* Gentamycin :~  80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials.~* Ornidazole :~  1. g per day (2 tablet per day), on day -2 and day -1; In tablets.
- 2)  MBP alone  group (Type: PLACEBO_COMPARATOR): Sennosides colonic preparation Oral placebo Gentamycin Oral placebo Ornidazole~* Sennosides colonic preparation (X-PREP) :~  1 per day, on day -2 and day -1.~* Placebo for oral gentamycin:~Same presentation as oral gentamycin x4 per day on day -2 and day -1. - Placebo for oral ornidazole : Same presentation as oral ornidazole~1g per day (2 tablet per day) on day -2 and day -1.
- 3)  Oral antibiotics alone  group (Type: EXPERIMENTAL): Oral Gentamycin Oral Ornidazole~* Gentamycin :~  80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials.~* Ornidazole :~  1. g per day (2 tablet per day), on day -2 and day -1; In tablets.
- 4)  No preparation  group (Type: PLACEBO_COMPARATOR): Oral placebo Gentamycin Oral placebo Ornidazole~- Placebo for oral gentamycin : Same presentation as oral gentamycin x4 per day on day -2 and day -1~- Placebo for oral ornidazole : Same presentation as oral ornidazole~1g per day (2 tablet per day) on day -2 and day -1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy